{"name":"Bial - Portela C S.A.","slug":"bial-portela-c-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"BIA 2-093","genericName":"BIA 2-093","slug":"bia-2-093","indication":"Other","status":"phase_2"},{"name":"BIA 3-202","genericName":"BIA 3-202","slug":"bia-3-202","indication":"Other","status":"phase_2"},{"name":"BIA 9-1067 25 mg","genericName":"BIA 9-1067 25 mg","slug":"bia-9-1067-25-mg","indication":"Other","status":"phase_1"},{"name":"BIA 9-1067 30 mg","genericName":"BIA 9-1067 30 mg","slug":"bia-9-1067-30-mg","indication":"Other","status":"phase_1"},{"name":"BIA 9-1067 5 mg","genericName":"BIA 9-1067 5 mg","slug":"bia-9-1067-5-mg","indication":"Other","status":"phase_1"},{"name":"BIA 9-1067 non-micronized","genericName":"BIA 9-1067 non-micronized","slug":"bia-9-1067-non-micronized","indication":"Other","status":"phase_1"},{"name":"ESL Banana taste","genericName":"ESL Banana taste","slug":"esl-banana-taste","indication":"Other","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"ESL","genericName":"ESL","slug":"esl","indication":"Partial-onset seizures (adjunctive therapy)","status":"marketed"},{"name":"ESL - Part II","genericName":"ESL - Part II","slug":"esl-part-ii","indication":"Partial-onset seizures (adjunctive therapy)","status":"phase_3"},{"name":"L-DOPA/DDCI","genericName":"L-DOPA/DDCI","slug":"l-dopa-ddci","indication":"Parkinson's disease","status":"marketed"},{"name":"Ongentys","genericName":"Ongentys","slug":"ongentys","indication":"Parkinson's disease","status":"marketed"},{"name":"levodopa/dopa decarboxylase inhibitor","genericName":"levodopa/dopa decarboxylase inhibitor","slug":"levodopa-dopa-decarboxylase-inhibitor","indication":"Parkinson's disease","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ESL Tutti-Frutti taste","genericName":"ESL Tutti-Frutti taste","slug":"esl-tutti-frutti-taste","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"BIA 2-093","genericName":"BIA 2-093","slug":"bia-2-093","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIA 3-202","genericName":"BIA 3-202","slug":"bia-3-202","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIA 9-1067 25 mg","genericName":"BIA 9-1067 25 mg","slug":"bia-9-1067-25-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIA 9-1067 30 mg","genericName":"BIA 9-1067 30 mg","slug":"bia-9-1067-30-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIA 9-1067 5 mg","genericName":"BIA 9-1067 5 mg","slug":"bia-9-1067-5-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIA 9-1067 non-micronized","genericName":"BIA 9-1067 non-micronized","slug":"bia-9-1067-non-micronized","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ESL","genericName":"ESL","slug":"esl","phase":"marketed","mechanism":"ESL (eslicarbazepine acetate) is a voltage-gated sodium channel blocker that reduces neuronal excitability and stabilizes seizure threshold.","indications":["Partial-onset seizures (adjunctive therapy)","Partial-onset seizures (monotherapy)"],"catalyst":""},{"name":"ESL - Part II","genericName":"ESL - Part II","slug":"esl-part-ii","phase":"phase_3","mechanism":"ESL (eslicarbazepine acetate) is a voltage-gated sodium channel blocker that reduces neuronal excitability to prevent seizures.","indications":["Partial-onset seizures (adjunctive therapy)","Generalized tonic-clonic seizures (adjunctive therapy)"],"catalyst":""},{"name":"ESL Banana taste","genericName":"ESL Banana taste","slug":"esl-banana-taste","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ESL Tutti-Frutti taste","genericName":"ESL Tutti-Frutti taste","slug":"esl-tutti-frutti-taste","phase":"phase_2","mechanism":"ESL works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"L-DOPA/DDCI","genericName":"L-DOPA/DDCI","slug":"l-dopa-ddci","phase":"marketed","mechanism":"L-DOPA is converted to dopamine in the brain to replace deficient neurotransmitter levels, while DDCI (a decarboxylase inhibitor) prevents premature conversion of L-DOPA in the periphery, allowing more to reach the central nervous system.","indications":["Parkinson's disease"],"catalyst":""},{"name":"Ongentys","genericName":"Ongentys","slug":"ongentys","phase":"marketed","mechanism":"Catechol O-methyltransferase, Catechol O-methyltransferase","indications":["Parkinson's disease"],"catalyst":""},{"name":"levodopa/dopa decarboxylase inhibitor","genericName":"levodopa/dopa decarboxylase inhibitor","slug":"levodopa-dopa-decarboxylase-inhibitor","phase":"marketed","mechanism":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while the dopa decarboxylase inhibitor prevents premature conversion in the periphery, allowing more levodopa to reach the brain.","indications":["Parkinson's disease","Restless legs syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxNVjNqUnRFNk51aWdrMUpSWHdaQUlaclNMb09JX1FSelUxb0R0b1JFX09OU29MMzh4cEFnTnljc2tINXBMWF9aWmpvUWI3T2lOeHRPLXZwRFBHdGxBdHE2Q3JjMzVmOS1raDJDbHNZeDJOU3pQS2RzMG9uOFBza2pnUTFaOFQ4c1FodE94ME5IUDZXZmlsR2hNaTZ0eTlwQ3RnTEZON0ZTV040OVRTM0Vtb3g3US1nTkZwQ0gtbGl1c0tmdE81U1pCS2tkZi03enNQSlpJUUtnRnRuVDBmUFpiUmI2V1Ffd1pFVFJNRWtfMWF2RDhNNUd5S0pQakcyM2hfclJmNG5ueW9FUjc2TGxCS2hfQThnMmdLM3BvWWlDVFlIX2dqVnJ6OC1IUllwOFBLejdTeGdEbjNXcktENV8xdGxlSUY?oc=5","date":"2026-01-29","type":"earnings","source":"Barchart.com","summary":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK, UCB Pharma - Barchar","headline":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Apti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQajZnS0M0MFE2VEtMMFk2aF8xYjVsQ1QxWldDWDc1WktybDJaU0RacXVvQW84cDJhbzhmVzJfUlNPTlZnS1VyQUhYa1NYR19rZzNZQ09wdU1FUjg0SDRpeGp0bEc3VF8wczU5ZzhCeDZtX2NxZ3NFLXlkdlNHMTNKbS02bWxQZW1vcTl4U194T1NuakNtVFFTSDNPVjEzYXlJSFBXc1JqZ3E5bWJqdU9kYllkTERUdw?oc=5","date":"2024-03-28","type":"regulatory","source":"lupin.com","summary":"Lupin Receives Approval from U.S. FDA for Eslicarbazepine Acetate Tablets - Lupin | Press Release - lupin.com","headline":"Lupin Receives Approval from U.S. FDA for Eslicarbazepine Acetate Tablets - Lupin | Press Release","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPUW4wVjJUZ0k0cUpTOFlvVXRzczA2TWR5NHFPUW40UjZOemljQ1hlVnRYN0VZOHM2c0pBUF81N05UbWdwTWZxS0dLSE1yZXNHOUdIZG9ILXUta094LWxqejlIbFJXeUJoYVFWZ0ZVYl9JM0lSWHlNQVZ3MjI1ZnpzR0JRb19mN2NkLVpBN0haTVp4RnRxRGlpd0Q5OUFHcEtzcGU5Q05yNUY?oc=5","date":"2016-01-17","type":"trial","source":"Forbes","summary":"Patient Dies In Phase I Trial Of Bial's Drug In France - Forbes","headline":"Patient Dies In Phase I Trial Of Bial's Drug In France","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"phase_2":4,"phase_1":4,"marketed":4,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}